Follicular Lymphoma

Follicular lymphoma (FL) is the most common type of the slow growing non-Hodgkin’s lymphomas. FL is derived from germinal center B cells and acquire genetic changes to develop into a malignant phenotype. BCR and its pathways appear to contribute to the survival of malignant cells.

FL accounts for one-third of non-Hodgkin lymphomas in adults. Median age at diagnosis is 60 years. This lymphoma usually responds well to initial treatment but is prone to relapses, sometimes transforming into high-grade NHL. The prognosis for individual patients can be estimated using the Follicular Lymphoma International Prognostic Index (FLIPI). Follicular lymphoma is not usually curable with conventional treatment. All patients usually receive rituximab as part of their treatment. However more patients are becoming rituximab refractory which has led to the research and development of new therapeutic agents.

2:31
Chemotherapy-free approaches in CLL, follicular lymphoma and DLBCL
Christian Buske
4:31
Overview of the GALLIUM study
Wolfgang Hiddemann
2:49
Overview of classical therapies for follicular lymphoma
Andrew Lister
4:14
Novel therapies for the treatment of CLL, MCL and FL
Nathan Hale Fowler
1:55
Ibrutinib in combination with rituximab – the future of treating FL
Nathan Hale Fowler
1:53
Relapsed follicular lymphoma: hope from a non-chemotherapy regimen of lenalidomide and obinutuzumab
Nathan Hale Fowler
2:46
Is obinutuzumab our key to improving the treatment of FL?
Wolfgang Hiddemann
1:26
Clinicogenetic risk models to predict outcome of follicular lymphoma patients
Sarah Huet
4:02
Key therapeutic advances in follicular lymphoma
Andrew Davies
1:01
Using models to predict progression in follicular lymphoma
Sarah Huet
2:53
Comparing the efficacy and safety of CT-P10 to rituximab in advanced stages follicular lymphoma
Christian Buske
2:07
Copanlisib produces promising results in relapsed/refractory follicular lymphoma
George Follows
2:41
ICML 2017 session on the biosimilar rituximab: challenges and data
Christian Buske
3:28
Top follicular lymphoma discussion points at ICML 2017
Andrew Lister
2:06
The combination of BGB-3111 and obinutuzumab for follicular lymphoma: promising preliminary results
Constantine Tam
2:46
The success story of indolent disease treatment expanded to difficult-to-treat patient groups
Graham Collins
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals